A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease

Wirta, David; Torkildsen, Gail; R. Moreira, Helen; Lonsdale, John; B. Ciolino, Joseph; Jentsch, Garrit; Beckert, Michael; W Ousler, George; Steven, Philipp; Krösser, Sonja

doi:10.1016/j.ophtha.2019.01.024

Public

A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease

Published in Ophthalmology • Jan 28, 2019

Authors:

David Wirta

Gail Torkildsen

Helen R. Moreira

Abstract

PURPOSE: To compare the efficacy, safety, and tolerability of waterfree cyclosporine formulation (CyclASol) at 2 concentrations (0.1% and 0.05% of cyclosporine [CsA]) to vehicle when applied twice daily for 16 weeks in patients with dry eye disease (DED). An open-label Restasis (Allergan, Irvine, CA...

Subject

Medicine

Tolerability

Randomized controlled trial

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!